Weekly Investment Analysts’ Ratings Updates for Praxis Precision Medicines (PRAX)

A number of firms have modified their ratings and price targets on shares of Praxis Precision Medicines (NASDAQ: PRAX) recently:

• 3/3/2025 – Praxis Precision Medicines had its price target lowered by analysts at Robert W. Baird from $117.00 to $73.00. They now have an “outperform” rating on the stock.
• 3/3/2025 – Praxis Precision Medicines had its price target lowered by analysts at Truist Financial Co. from $175.00 to $85.00. They now have a “buy” rating on the stock.
• 3/3/2025 – Praxis Precision Medicines had its price target lowered by analysts at HC Wainwright from $120.00 to $105.00. They now have a “buy” rating on the stock.
• 3/3/2025 – Praxis Precision Medicines had its price target lowered by analysts at Needham & Company LLC from $150.00 to $85.00. They now have a “buy” rating on the stock.
• 2/28/2025 – Praxis Precision Medicines was downgraded by analysts at Wedbush from a “hold” rating to a “strong sell” rating.
• 2/11/2025 – Praxis Precision Medicines is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $111.00 price target on the stock.
• 2/10/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $150.00 price target on the stock.
• 1/21/2025 – Praxis Precision Medicines had its price target raised by analysts at Truist Financial Co. from $150.00 to $175.00. They now have a “buy” rating on the stock.

Praxis Precision Medicines Trading Down 5.4 %

Shares of Praxis Precision Medicines stock opened at $36.82 on Wednesday. The firm has a market capitalization of $742.40 million, a P/E ratio of -3.57 and a beta of 2.76. The business has a fifty day simple moving average of $66.51 and a two-hundred day simple moving average of $68.52. Praxis Precision Medicines, Inc. has a 12 month low of $30.01 and a 12 month high of $91.83.

Praxis Precision Medicines (NASDAQ:PRAX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($2.94) earnings per share for the quarter, missing the consensus estimate of ($2.76) by ($0.18). Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative return on equity of 54.86%. The company had revenue of $7.48 million for the quarter, compared to the consensus estimate of $0.36 million. Analysts predict that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current year.

Institutional Investors Weigh In On Praxis Precision Medicines

Several large investors have recently bought and sold shares of PRAX. GF Fund Management CO. LTD. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at about $48,000. Graham Capital Management L.P. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at about $209,000. KLP Kapitalforvaltning AS bought a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at about $215,000. Finally, Intech Investment Management LLC bought a new stake in shares of Praxis Precision Medicines during the 3rd quarter valued at about $217,000. 67.84% of the stock is currently owned by institutional investors.

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.